Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease

Hepatology

Volumn 51, Issue 1, 2010, Pages 111-120

  Bell, Lauren N ^a   Theodorakis, Janice L ^b   Vuppalanchi, Raj ^a   Saxena, Romil ^a   Bemis, Kerry G ^b   Wang, Mu ^a,b   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY   (United States)

^b Monarch LifeSciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; CARRIER PROTEIN; PROTEOME;

ADULT; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EXTRACELLULAR MATRIX; FATTY LIVER; FEMALE; HUMAN; IMMUNOREGULATION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; PROTEOMICS;

EID: 73449090429     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23271     Document Type: Article

References (45)

1. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003;124:248-250.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
3. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
4. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. HEPATOLOGY 1995;22:1714-1719.
5. McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, Hall P, et al., eds. Fatty Liver Disease: NASH and Related Disorders. Oxford, UK: Blackwell; 2005:23-37.
6. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. HEPATOLOGY 2009;49:306-317.
7. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006;40:34-38.
8. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750.
9. Chave G, Milot T, Pilleul F. Out of phase magnetic resonance imaging and liver applications. J Radiol 2005;86:993-997.
10. Suzuki A, Angulo P, Lymph J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-786.
11. Degertegin B, Ozenirler S, Elberg S, Akyol G. Serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci 2007;52:2622-2628.
12. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that accurately identifies liver fibrosis in patients with NAFLD. HEPATOLOGY 2007;45:846-853.
13. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. HEPATOLOGY 2008;47:455-460.
14. Wang M, You J, Bemis KG, Tegeler TJ, Brown DP. Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Brief Funct Genomic Proteomics 2008;7:329-339.
15. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. HEPATOLOGY 2003;37:544-550.
16. Chalasani N, Deeg MA, Persohn S, Crabb DW. Metabolic and anthropometric evaluation of insulin resistance in non-diabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:1849-1855.
17. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497-1502.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
19. Hale JE, Butler JP, Gelfanova V, You JS, Knierman MD. A simplified procedure for the reduction and alkylation of cysteine residues in proteins prior to proteolytic digestion and mass spectral analysis. Anal Biochem 2004;333:174-181.
20. Higgs RE, Knierman MD, Gelfanova V, Butler JP, Hale JE. Comprehensive label-free method for the relative quantification of proteins from biological samples. J Proteome Res 2005;4:1442-1450.
21. Craig R, Beavis RC. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004;20:1466-1467.
22. Eng J, McCormack A, Yates RR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994;5:976-989.
23. Higgs RE, Knierman MD, Freeman AB, Gelbert LM, Patil ST, Hale JE. Estimating the statistical significance of peptide identifications from shotgun proteomics experiments. J Proteome Res 2007;6:1758-1767.
24. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193.
25. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. HEPATOLOGY 2005;42:665-674.
26. Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, et al. Differential expression of lumican and fatty acid binding protein-1 - new insights into the histologic spectrum of non-alcoholic fatty liver disease. HEPATOLOGY 2009;49:1375-1384.
27. Yan W, Chen SS. Mass spectrometry-based quantitative proteomic profiling. Brief Funct Genomic Proteomics 2005;4:27-38.
28. Zhang B, VerBerkmoes NC, Langston MA, Uberbacher E, Hettich RL, Samatoma NF. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res 2006;5:2909-2918.
29. Wang G, Wu WW, Zeng W, Chou CL, Shen RF. Label-free protein quantification using LC-coupled ion trap or FT mass spectrometry: reproducibility, linearity, and application with complex proteomes. J Proteome Res 2006;5:1214-1223.
30. Ono M, Shitashige M, Honda K, Isobe T, Kuwabara H, Matsuzuki H, et al. Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006;5:1338-1347.
31. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-362.
32. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-2263.
33. Janke J, Engeli S, Boschmann M, Adams F, Böhnke J, Luft FC, et al. Retinolbinding protein 4 in human obesity. Diabetes 2006;55:2805-2810.
34. Seo JA, Kim NH, Park SY, Kim HY, Ryu OH, Lee KW, et al. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol 2007;68:555-560.
35. Nobili V, Alkhouri N, Alisi A, Ottino S, Lopez R, Manco M, et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:575-579.
36. Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol 2003;14:12-17.
37. Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009;87:143-152.
38. Chaerkady R, Harsha HC, Nalli A, Gucek M, Vivekanandan P, Akhtar J, et al. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J Proteome Res 2008;7:4289-4298.
39. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 2004;36:231-242.
40. Bell AW. Lipid metabolism in liver and selected tissues and in the whole body of ruminant animals. Prog Lipid Res 1979;18:117-164.
41. Tietge UJ, Boker KH, Bahr MJ, Weinberg S, Pichlmayr R, SchmidtHH,et al. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology 1998;45:2255-2260.
42. Sherlock S. Alcoholic liver disease. Lancet 1995;345:227-229.
43. Gobel T, Vorderwulbecke S, Hauck K, Fey H, Haussinger D, Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006;12:7604-7612.
44. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009;46:83-106.
45. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin Liver Dis 2004;24:349-362.